Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa.

ABSTRACT:

Objective

Patients with Lynch syndrome (LS) are at markedly increased risk for colorectal cancer. It is being increasingly recognised that the immune system plays an essential role in LS tumour development, thus making an ideal target for cancer prevention. Our objective was to evaluate the safety, assess the activity and discover novel molecular pathways involved in the activity of naproxen as primary and secondary chemoprevention in patients with LS.

Design

We conducted a Phase Ib, placebo-controlled, randomised clinical trial of two dose levels of naproxen sodium (440 and 220 mg) administered daily for 6 months to 80 participants with LS, and a co-clinical trial using a genetically engineered mouse model of LS and patient-derived organoids (PDOs).

Results

Overall,

SUBMITTER: Reyes-Uribe L 

PROVIDER: S-EPMC7790993 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature